SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S
Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS) for Treatment of Patients with Acute Myeloid Leukemia (AML)NEW YORK, April 26,...
Month: April 2022
Panbela Schedules Conference Call on May 12, 2022, to Report 2022 First Quarter Financial Results
MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for...
Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet...
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada,...
Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®
Reinforces Company’s Robust Intellectual Property PortfolioSOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a...
Better Choice Company to Host First Quarter 2022 Earnings Call on May 12th at 8:30 a.m. ET
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet...
Quotient Limited Announces Appointment of New Board Member
JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the...
Vivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vivos Method
New Pneusomnia Center in Toluca Lake, Calif., Will Combine Medical and Dental Expertise to Provide Comprehensive Care for Complex Airway...
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric...
Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA
Proof-of-concept studies go beyond typical DNA data storage projects to ensure high-fidelity data recovery within an automated synthetic biology workflowSAN...
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR)WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq:...
Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022
MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity...
electroCore Completes Sale of New Jersey Tax Benefits
ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that...
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
Shape Therapeutics Welcomes Google and Stripe Veterans Gayathri Rajan, Kelly Sims to its Board of Directors
Rajan, Sims bring unique platform technology experience to help build the next generation of RNA medicineSEATTLE, April 26, 2022 (GLOBE...
Agile Therapeutics Announces 1-For-40 Reverse Stock Split
PRINCETON, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that...
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically...
Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the...
SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer
CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)The trial will enroll up to...
89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)
Webinar to feature presentations from Harold Bays, MD, and Deepak L. Bhatt, MD, MPH, on Wednesday, May 4th at 11:00...
